688117 圣诺生物
午间休市 03-13 11:29:37
资讯
新帖
简况
圣诺生物(688117.SH)：利那洛肽原料药获得上市申请批准通知书
智通财经网 · 03-04
圣诺生物(688117.SH)：利那洛肽原料药获得上市申请批准通知书
每周股票复盘：圣诺生物（688117）2025年净利增231.49%
证券之星 · 03-01
每周股票复盘：圣诺生物（688117）2025年净利增231.49%
圣诺生物（688117）披露2025年度业绩快报，2月27日股价下跌1.59%
证券之星 · 02-27
圣诺生物（688117）披露2025年度业绩快报，2月27日股价下跌1.59%
圣诺生物(688117.SH)部分产品拟中选新一轮接续采购
智通财经 · 02-11
圣诺生物(688117.SH)部分产品拟中选新一轮接续采购
BFB HEALTH与圣诺生物签署战略合作协议
人民财讯 · 01-22
BFB HEALTH与圣诺生物签署战略合作协议
每周股票复盘：圣诺生物（688117）2025净利预增204.42%至280.53%
证券之星 · 01-18
每周股票复盘：圣诺生物（688117）2025净利预增204.42%至280.53%
净利润预增超200％，圣诺生物借GLP-1减肥赛道大口“吃肉”
华夏时报网 · 01-16
净利润预增超200％，圣诺生物借GLP-1减肥赛道大口“吃肉”
圣诺生物：预计2025年全年归属净利润盈利1.52亿元至1.9亿元
证券之星 · 01-15
圣诺生物：预计2025年全年归属净利润盈利1.52亿元至1.9亿元
1月7日圣诺生物涨7.28%，华商智能生活灵活配置混合A基金重仓该股
证券之星 · 01-07
1月7日圣诺生物涨7.28%，华商智能生活灵活配置混合A基金重仓该股
每周股票复盘：圣诺生物（688117）GLP-1合同履约不达预期
证券之星 · 01-02
每周股票复盘：圣诺生物（688117）GLP-1合同履约不达预期
圣诺生物（688117）披露董事会换届选举结果，12月17日股价上涨2.56%
证券之星 · 2025-12-17
圣诺生物（688117）披露董事会换届选举结果，12月17日股价上涨2.56%
圣诺生物：12月12日高管王晓莉减持股份合计21.16万股
证券之星 · 2025-12-14
圣诺生物：12月12日高管王晓莉减持股份合计21.16万股
12月12日圣诺生物现1笔折价11.8%的大宗交易 合计成交792.39万元
证券之星 · 2025-12-12
12月12日圣诺生物现1笔折价11.8%的大宗交易 合计成交792.39万元
12月10日圣诺生物发布公告，股东减持314.79万股
证券之星 · 2025-12-10
12月10日圣诺生物发布公告，股东减持314.79万股
圣诺生物（688117）披露拟换届选举第五届董事会，12月09日股价下跌1.87%
证券之星 · 2025-12-09
圣诺生物（688117）披露拟换届选举第五届董事会，12月09日股价下跌1.87%
圣诺生物(688117.SH)：五肽-18通过化妆品新原料备案
智通财经 · 2025-12-03
圣诺生物(688117.SH)：五肽-18通过化妆品新原料备案
圣诺生物（688117）披露拟换届董事会人选，12月02日股价下跌0.99%
证券之星 · 2025-12-02
圣诺生物（688117）披露拟换届董事会人选，12月02日股价下跌0.99%
圣诺生物最新公告：董事、高管拟合计减持不超0.024%股份
证券之星 · 2025-11-30
圣诺生物最新公告：董事、高管拟合计减持不超0.024%股份
11月26日圣诺生物涨6.99%，华商智能生活灵活配置混合A基金重仓该股
证券之星 · 2025-11-26
11月26日圣诺生物涨6.99%，华商智能生活灵活配置混合A基金重仓该股
每周股票复盘：圣诺生物（688117）维培那肽原料药获上市批准
证券之星 · 2025-11-23
每周股票复盘：圣诺生物（688117）维培那肽原料药获上市批准
暂无数据
公司概况
公司名称：
成都圣诺生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2021-06-03
主营业务：
成都圣诺生物科技股份有限公司的主营业务是多肽原料药和制剂产品的研发、生产与销售，同时提供多肽创新药药学研究服务、多肽类产品定制生产服务以及左西孟旦制剂代加工和左西孟旦原料药生产与出口。公司的主要产品是多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。
发行价格：
17.90
{"stockData":{"symbol":"688117","market":"SH","secType":"STK","nameCN":"圣诺生物","latestPrice":37.78,"timestamp":1773372577000,"preClose":37.8,"halted":0,"volume":385178,"delay":0,"changeRate":-0.0005,"floatShares":157000000,"shares":157000000,"eps":0.7631,"marketStatus":"午间休市","change":-0.02,"latestTime":"03-13 11:29:37","open":37.72,"high":37.93,"low":37.51,"amount":14511200,"amplitude":0.0111,"askPrice":37.78,"askSize":44,"bidPrice":37.73,"bidSize":5,"shortable":0,"etf":0,"ttmEps":0.7631,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773378000000},"marketStatusCode":3,"adr":0,"adjPreClose":37.8,"symbolType":"stock_kcb","openAndCloseTimeList":[[1773365400000,1773372600000],[1773378000000,1773385200000]],"highLimit":41.58,"lowLimit":34.02,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":157385978,"isCdr":false,"pbRate":5.77,"roa":"--","peRate":49.508583,"roe":"12.94%","epsLYR":0.45,"committee":-0.625899,"marketValue":5946000000,"turnoverRate":0.0024,"status":1,"floatMarketCap":5946000000},"requestUrl":"/m/hq/s/688117/tweets","defaultTab":"tweets","newsList":[{"id":"2616580787","title":"圣诺生物(688117.SH)：利那洛肽原料药获得上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616580787","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616580787?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:38","pubTimestamp":1772613484,"startTime":"0","endTime":"0","summary":"圣诺生物(688117.SH)发布公告，公司全资子公司成都圣诺生物制药有限公司于近日收到国家药品监督管理局签发的关于利那洛肽原料药的《化学原料药上市申请批准通知书》。","market":"us","thumbnail":"https://img.zhitongcaijing.com/astock/18.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/18.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"圣诺生物(688117.SH)：利那洛肽原料药获得上市申请批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2616481608","title":"每周股票复盘：圣诺生物（688117）2025年净利增231.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616481608","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616481608?lang=zh_cn&edition=full","pubTime":"2026-03-01 01:19","pubTimestamp":1772299148,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，圣诺生物报收于38.32元，较上周的38.66元下跌0.88%。本周关注点来自业绩披露要点：圣诺生物2025年归属净利润同比增长231.49%。业绩披露要点圣诺生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润盈利1.658亿元，同比增长231.49%。公司公告汇总成都圣诺生物科技股份有限公司发布2025年度业绩快报，营业总收入741,343,445.99元，同比增长62.55%；营业利润200,844,661.43元，同比增长223.63%；归属于母公司所有者的净利润165,823,888.08元，同比增长231.49%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"gpt_icon":0},{"id":"2614303854","title":"圣诺生物（688117）披露2025年度业绩快报，2月27日股价下跌1.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614303854","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614303854?lang=zh_cn&edition=full","pubTime":"2026-02-27 22:14","pubTimestamp":1772201660,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，圣诺生物报收于38.32元，较前一交易日下跌1.59%，最新总市值为60.31亿元。该股当日开盘38.66元，最高38.94元，最低38.1元，成交额达1.32亿元，换手率为2.18%。近日，成都圣诺生物科技股份有限公司发布2025年度业绩快报，营业总收入741,343,445.99元，同比增长62.55%；营业利润200,844,661.43元，同比增长223.63%；归属于母公司所有者的净利润165,823,888.08元，同比增长231.49%。扣除非经常性损益后的净利润同比增长278.52%。公司总资产193,712.57万元，较期初增长17.55%；股本因资本公积金转增增至157,385,978股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700042215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"gpt_icon":0},{"id":"2610984691","title":"圣诺生物(688117.SH)部分产品拟中选新一轮接续采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2610984691","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610984691?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:20","pubTimestamp":1770798016,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 圣诺生物(688117.SH)发布公告，公司全资子公司成都圣诺生物制药有限公司于近日参与了国家组织的第一批至第八批国家集采药品新一轮接续采购工作，本次接续采购是国家组织集采的化学药品首次开展全国范围统一接续，根据《国家组织集采药品协议期满品种接续采购拟中选结果表》(LC-YPJX-2026-1)显示，公司产品醋酸奥曲肽注射剂(第七批中选)、醋酸阿托西班注射剂(第八批中选)、生长抑素注射剂(第八批中选)与公司新中选产品胸腺法新注射剂、依替巴肽注射剂共同拟中选本次新一轮接续采购。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2605977524","title":"BFB HEALTH与圣诺生物签署战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2605977524","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605977524?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:29","pubTimestamp":1769092149,"startTime":"0","endTime":"0","summary":"人民财讯1月22日电，1月22日，港股上市公司财讯传媒集团有限公司（00205.HK）正式更名为“BFBHealthLimited”，中文股票简称由“财讯传媒”更改为“BFBHEALTH”。此外，当日，BFBHEALTH宣布与A股科创板上市公司圣诺生物签署战略合作协议，双方将在生物健康领域展开深度合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627744480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688117"],"gpt_icon":0},{"id":"2604928275","title":"每周股票复盘：圣诺生物（688117）2025净利预增204.42%至280.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604928275","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604928275?lang=zh_cn&edition=full","pubTime":"2026-01-18 01:55","pubTimestamp":1768672510,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，圣诺生物报收于42.64元，较上周的44.36元下跌3.88%。本周，圣诺生物1月12日盘中最高价报46.5元。本周关注点业绩披露要点：圣诺生物预计2025年归母净利润同比增长204.42%至280.53%。公司公告汇总成都圣诺生物科技股份有限公司预计2025年度实现归属于母公司所有者的净利润15,228.31万元至19,035.38万元，同比增长204.42%至280.53%；扣除非经常性损益后的净利润为14,872.70万元至18,590.88万元，同比增长226.07%至307.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2603986959","title":"净利润预增超200％，圣诺生物借GLP-1减肥赛道大口“吃肉”","url":"https://stock-news.laohu8.com/highlight/detail?id=2603986959","media":"华夏时报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603986959?lang=zh_cn&edition=full","pubTime":"2026-01-16 19:02","pubTimestamp":1768561320,"startTime":"0","endTime":"0","summary":"2026年1月15日晚间，成都圣诺生物科技股份有限公司发布2025年度业绩预告。供需矛盾凸显 GLP-1类药物减肥适应症的突破，成为引爆全球市场的关键，推动其需求从医疗场景延伸至消费市场。 综合来看，圣诺生物2025年的业绩高增长，是其精准抓住GLP-1全球供应链机遇的结果，具有明显的周期性和结构性特征。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-16/doc-inhhnzat5490220.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-16/doc-inhhnzat5490220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688117","GLP"],"gpt_icon":0},{"id":"2603605611","title":"圣诺生物：预计2025年全年归属净利润盈利1.52亿元至1.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603605611","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603605611?lang=zh_cn&edition=full","pubTime":"2026-01-15 18:00","pubTimestamp":1768471237,"startTime":"0","endTime":"0","summary":"证券之星消息，圣诺生物发布业绩预告，预计2025年全年归属净利润盈利1.52亿元至1.9亿元。圣诺生物2025年三季报显示，前三季度公司主营收入5.2亿元，同比上升53.96%；归母净利润1.27亿元，同比上升123.03%；扣非净利润1.26亿元，同比上升134.97%；其中2025年第三季度，公司单季度主营收入1.83亿元，同比上升31.43%；单季度归母净利润3805.35万元，同比上升8.23%；单季度扣非净利润3659.84万元，同比上升5.98%；负债率45.95%，投资收益105.57万元，财务费用1111.45万元，毛利率56.67%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500029892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117"],"gpt_icon":0},{"id":"2601827199","title":"1月7日圣诺生物涨7.28%，华商智能生活灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601827199","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601827199?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:33","pubTimestamp":1767771228,"startTime":"0","endTime":"0","summary":"证券之星消息，1月7日圣诺生物涨7.28%，收盘报41.25元，换手率5.48%，成交量8.63万手，成交额3.47亿元。重仓圣诺生物的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级1家，增持评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为华商基金的华商智能生活灵活配置混合A。华商智能生活灵活配置混合A目前规模为2.37亿元，最新净值2.017，较上一交易日下跌0.05%，近一年上涨78.5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700017950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"gpt_icon":0},{"id":"2600035189","title":"每周股票复盘：圣诺生物（688117）GLP-1合同履约不达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2600035189","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600035189?lang=zh_cn&edition=full","pubTime":"2026-01-02 01:54","pubTimestamp":1767290053,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，圣诺生物报收于40.89元，较上周的40.15元上涨1.84%。本周，圣诺生物12月26日盘中最高价报41.16元。圣诺生物当前最新总市值59.48亿元，在化学制药板块市值排名88/150，在两市A股市值排名2955/5181。因终端客户产品商业化进展滞后，未实际履行商业化订单，合同履行进展不达预期。公司已收到后续合作意向，但尚未签订正式合同，未来采购金额及利润贡献暂无法预计。该事项不会对公司本年度经营业绩或财务状况产生重大不利影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"gpt_icon":0},{"id":"2592379916","title":"圣诺生物（688117）披露董事会换届选举结果，12月17日股价上涨2.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592379916","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592379916?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:37","pubTimestamp":1765982228,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘，圣诺生物报收于41.33元，较前一交易日上涨2.56%，最新总市值为65.05亿元。近日，成都圣诺生物科技股份有限公司召开2025年第一次临时股东会，审议通过董事会换届选举议案。出席会议股东所持表决权占公司总表决权的40.7476%，所有议案均获有效通过，中小投资者已单独计票。北京海润天睿律师事务所对本次会议出具法律意见书，确认会议召集、召开程序及表决结果合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700040190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2591265706","title":"圣诺生物：12月12日高管王晓莉减持股份合计21.16万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591265706","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591265706?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:01","pubTimestamp":1765699266,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月14日市场公开信息、上市公司公告及交易所披露数据整理，圣诺生物最新董监高及相关人员股份变动情况：2025年12月12日公司副总经理,董事王晓莉共减持公司股份21.16万股，占公司总股本为0.1345%。变动期间公司股价上涨2.06%，12月12日当日收盘报41.69元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121400002048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"gpt_icon":0},{"id":"2590577352","title":"12月12日圣诺生物现1笔折价11.8%的大宗交易 合计成交792.39万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590577352","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590577352?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:57","pubTimestamp":1765533460,"startTime":"0","endTime":"0","summary":"证券之星消息，12月12日圣诺生物发生大宗交易，交易数据如下：大宗交易成交价格36.77元，相对当日收盘价折价11.8%，成交21.55万股，成交金额792.39万元，买方营业部为西南证券股份有限公司重庆长寿证券营业部，卖方营业部为招商证券股份有限公司成都人民南路证券营业部。近三个月该股共发生29笔大宗交易，合计成交2.45万手，折价成交29笔。截至2025年12月12日收盘，圣诺生物报收于41.69元，上涨2.06%，换手率3.09%，成交量4.86万手，成交额2.0亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200029073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2590581050","title":"12月10日圣诺生物发布公告，股东减持314.79万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590581050","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590581050?lang=zh_cn&edition=full","pubTime":"2025-12-10 20:01","pubTimestamp":1765368082,"startTime":"0","endTime":"0","summary":"证券之星消息，12月10日圣诺生物发布公告《圣诺生物:简式权益变动报告书(川发投资)》，其股东四川发展证券投资基金管理有限公司-四川资本市场纾困发展证券投资基金合伙企业(有限合伙)于2025年9月18日至2025年12月10日间合计减持314.79万股，占公司目前总股本的2.0001%，变动期间该股股价上涨4.99%，截止12月10日收盘报41.44元。股东增减持详情见下表：根据圣诺生物2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000035547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2590342599","title":"圣诺生物（688117）披露拟换届选举第五届董事会，12月09日股价下跌1.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590342599","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590342599?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:26","pubTimestamp":1765290383,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘，圣诺生物报收于39.8元，较前一交易日下跌1.87%，最新总市值为62.64亿元。该股当日开盘40.6元，最高41.0元，最低39.75元，成交额达9478.38万元，换手率为1.5%。公司近日发布公告称，成都圣诺生物科技股份有限公司将于2025年12月17日召开2025年第一次临时股东会，审议董事会换届选举相关议案。各候选人简历详见公司于2025年12月2日披露的公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900041126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2588012048","title":"圣诺生物(688117.SH)：五肽-18通过化妆品新原料备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2588012048","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588012048?lang=zh_cn&edition=full","pubTime":"2025-12-03 18:07","pubTimestamp":1764756424,"startTime":"0","endTime":"0","summary":"智通财经APP讯，圣诺生物(688117.SH)发布公告，公司全资子公司成都凯捷多肽科技有限公司的化妆品原料五肽-18于近日通过国家药品监督管理局化妆品新原料备案。公司本次备案成功的化妆品新原料五肽-18是一种可用于各类化妆品的皮肤保护剂，在化妆品成品中的安全使用量可达1.86%。通过协助改善皮肤刺激状态等，从而达到皮肤保护的作用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"圣诺生物(688117.SH)：五肽-18通过化妆品新原料备案","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2588803181","title":"圣诺生物（688117）披露拟换届董事会人选，12月02日股价下跌0.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588803181","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588803181?lang=zh_cn&edition=full","pubTime":"2025-12-02 17:54","pubTimestamp":1764669284,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，圣诺生物报收于39.2元，较前一交易日下跌0.99%，最新总市值为61.7亿元。该股当日开盘39.22元，最高39.96元，最低38.68元，成交额达9955.13万元，换手率为1.63%。本次会议主要审议关于公司董事会换届选举第五届董事会非独立董事和独立董事的议案，共提名6名非独立董事和3名独立董事候选人。股权登记日为2025年12月10日，股东可于2025年12月12日前办理参会登记。公告显示，会议不涉及关联股东回避表决及优先股股东参与表决事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200027285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2587796707","title":"圣诺生物最新公告：董事、高管拟合计减持不超0.024%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2587796707","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587796707?lang=zh_cn&edition=full","pubTime":"2025-11-30 16:10","pubTimestamp":1764490247,"startTime":"0","endTime":"0","summary":"圣诺生物(688117.SH)公告称，公司副总经理马中刚计划减持不超过1.88万股，即不超过公司总股本的0.0120%；董事、副总经理、财务负责人伍利计划减持不超过1.88万股，即不超过公司总股本的0.0120%。减持方式为集中竞价或大宗交易，减持原因为个人资金需求，减持期间为2025年12月23日至2026年3月22日。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025113000002388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"gpt_icon":0},{"id":"2586395862","title":"11月26日圣诺生物涨6.99%，华商智能生活灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586395862","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586395862?lang=zh_cn&edition=full","pubTime":"2025-11-26 15:33","pubTimestamp":1764142390,"startTime":"0","endTime":"0","summary":"证券之星消息，11月26日圣诺生物涨6.99%，收盘报42.1元，换手率6.57%，成交量10.33万手，成交额4.34亿元。重仓圣诺生物的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为华商基金的华商智能生活灵活配置混合A。华商智能生活灵活配置混合A目前规模为2.37亿元，最新净值1.754，较上一交易日上涨4.97%，近一年上涨43.77%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600017603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2585278105","title":"每周股票复盘：圣诺生物（688117）维培那肽原料药获上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2585278105","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585278105?lang=zh_cn&edition=full","pubTime":"2025-11-23 04:09","pubTimestamp":1763842152,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，圣诺生物报收于38.09元，较上周的38.77元下跌1.75%。本周，圣诺生物11月17日盘中最高价报39.36元。11月19日盘中最低价报36.27元。圣诺生物当前最新总市值59.95亿元，在化学制药板块市值排名87/151，在两市A股市值排名2791/5167。维培那肽为聚乙二醇化艾塞那肽，属于GLP-1受体激动剂，可用于治疗2型糖尿病和肥胖症。此次获批符合药品注册相关要求，生产工艺、质量标准和包装标签按所附执行。具体销售情况受政策和市场环境影响存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300001137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773376229709,"stockEarnings":[{"period":"1week","weight":0.0413},{"period":"1month","weight":-0.033},{"period":"3month","weight":-0.0933},{"period":"6month","weight":-0.0721},{"period":"1year","weight":1.3596},{"period":"ytd","weight":0.0003}],"compareEarnings":[{"period":"1week","weight":0.005},{"period":"1month","weight":0.0002},{"period":"3month","weight":0.0616},{"period":"6month","weight":0.0668},{"period":"1year","weight":0.2246},{"period":"ytd","weight":0.0404}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都圣诺生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10072人(较上一季度减少9.53%)","perCapita":"15626股","listingDate":"2021-06-03","address":"四川省成都市大邑县大安路98号","registeredCapital":"15738万元","survey":" 成都圣诺生物科技股份有限公司的主营业务是多肽原料药和制剂产品的研发、生产与销售，同时提供多肽创新药药学研究服务、多肽类产品定制生产服务以及左西孟旦制剂代加工和左西孟旦原料药生产与出口。公司的主要产品是多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。","listedPrice":17.9},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"圣诺生物(688117)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供圣诺生物(688117)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"圣诺生物,688117,圣诺生物股票,圣诺生物股票老虎,圣诺生物股票老虎国际,圣诺生物行情,圣诺生物股票行情,圣诺生物股价,圣诺生物股市,圣诺生物股票价格,圣诺生物股票交易,圣诺生物股票购买,圣诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"圣诺生物(688117)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供圣诺生物(688117)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}